Emcure Pharmaceuticals IPO Details: The IPO dates for Emcure Pharmaceuticals have been set, with the offering opening on July 3, 2024, and closing on July 5, 2024. Emcure Pharmaceuticals aims to raise approximately ₹1952.03 crores through this IPO, which includes a fresh issue of ₹800 crores and an offer for sale of up to 11,428,839 equity shares at ₹5 each. The allocation is 35% for retail investors, 50% for Qualified Institutional Buyers (QIB), and 15% for High Net-worth Individuals (HNI).
Emcure Pharmaceuticals, an Indian company, is renowned for developing, manufacturing, and marketing a diverse range of pharmaceutical products globally across major therapeutic areas. Their focus on research and development has led to a unique product portfolio encompassing orals, injectables, and biotherapeutics, allowing them to penetrate over 70 countries, including strong markets in India, Europe, and Canada. In the MAT Financial Year 2024, they were recognized as the 13th largest pharmaceutical company in India by Domestic Sales, the 4th largest by market share in their Covered Markets, and the leading company in gynecology and HIV antivirals in India (Source: CRISIL Report). The company benefits from the expertise of experienced promoters and a robust professional management team.
Their competitive edge in the domestic market is attributed to their diverse product portfolio, which has established their presence in significant therapeutic areas such as gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related, and oncology/anti-neoplastics. In these areas, they were ranked among the top 10 pharmaceutical companies in India by Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
Key product lines like iron, chiral, biotherapeutics, injectables, and photochemistry contributed 52.97% of their revenue from sales in India for the Financial Year 2024, highlighting their strategy of maintaining a differentiated portfolio. Emcure focuses on pharmaceutical products for chronic and sub-chronic therapeutic areas, which are projected to grow faster than acute therapeutic areas over the next five years (Source: CRISIL Report). Chronic therapeutic areas accounted for ₹25,460.48 million or 46.22% of their total Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
Objects of the Issue
Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by the company.
General corporate purposes.
Emcure Pharmaceuticals IPO Review (Apply or Not)
To be updated soon
Brokerage Firm IPO Review
- Capital Market: To be updated soon
- Religare Broking: To be updated soon
- Hem Securities: To be updated soon
- Arihant Capital: To be updated soon
Emcure Pharmaceuticals IPO Date & Price Band Details
| IPO Open: | July 3, 2024 |
| IPO Close: | July 5, 2024 |
| IPO Size: | Approx ₹1952.03 Crores, 19,365,346 Equity Share |
| Fresh Issue: | Approx ₹800 Crores, 7,936,507 Equity Share |
| Offer for Sale: | Approx ₹1152.03, 11,428,839 Equity Share |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹960 to ₹1008 Per Share |
| IPO Listing on: | BSE & NSE |
| Retail Quota: | 35% |
| QIB Quota: | 50% |
| NII Quota: | 15% |
| Discount: | ₹90 Per Share for Employees |
Emcure Pharmaceuticals IPO (Emcure Pharma IPO) Market Lot
The minimum market lot for the Emcure Pharmaceuticals IPO is 14 shares, requiring an application amount of ₹14,112. Retail investors can apply for up to 14 lots, which totals 196 shares or ₹197,568.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 14 | ₹ 14,112 |
| Retail Maximum | 14 | 196 | ₹ 1,97,568 |
| S-HNI Minimum | 15 | 210 | ₹ 2,11,680 |
| B-HNI Minimum | 71 | 994 | ₹ 10,01,952 |
Emcure Pharmaceuticals IPO (Emcure Pharma IPO) Allotment & Listing Dates
The Emcure Pharmaceuticals IPO opens on July 3 and closes on July 5. The allotment will be finalized on July 8, with the listing scheduled for July 10.
| IPO Open Date: | July 3, 2024 |
| IPO Close Date: | July 5, 2024 |
| Basis of Allotment: | July 8, 2024 |
| Refunds: | July 9, 2024 |
| Credit to Demat Account: | July 9, 2024 |
| IPO Listing Date: | July 10, 2024 |
Emcure Pharmaceuticals Limited Financials
Emcure Pharmaceuticals Limited’s revenue increased by 11.33%, while profit after tax (PAT) decreased by 6.1% between the financial years ending March 31, 2023, and March 31, 2024.
| Amount in ₹ Crore | |||
| Period Ended | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
| Assets | 7,806.16 | 6,672.53 | 6,063.47 |
| Revenue | 6,715.24 | 6,031.72 | 5,918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| Net Worth | 2,952.28 | 2,501.13 | 1,987.55 |
| Reserves and Surplus | 2,722.40 | 2,293.77 | 1,791.03 |
| Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
Key Performance Indicator
The Emcure Pharma IPO market capitalization is Rs 19029.89 Cr.
| KPI | Values |
| ROE | 16.90% |
| ROCE | 19.37% |
| Debt/Equity | 0.67 |
| RoNW | 16.87% |
| P/BV | 6.18 |
Emcure Pharmaceuticals (Emcure Pharma) IPO GMP Today:
Note: The IPO GMP prices listed here are based on grey market news. We do not engage in or endorse trading in the grey market or dealing with grey market rates (sub2).
Emcure Pharmaceuticals IPO (Emcure Pharma IPO) Valuation
Check Emcure Pharmaceuticals IPO (Emcure Pharma IPO) valuation details, including Earnings Per Share (EPS), Price/Earnings (P/E) Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV).
| Earning Per Share (EPS): | ₹27.54 per Equity Share |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 16.87% |
| Net Asset Value (NAV): | ₹163.22 per Equity Share |
Peer Group
• Dr. Reddy’s Laboratories Limited
• Cipla Limited
• Alkem Laboratories Limited
• Torrent Pharmaceuticals Limited
• Mankind Pharma Limited
• Abbott India Limited
• J. B. Chemicals & Pharmaceuticals Limited
Company Promoters
• Satish Mehta
• Sunil Mehta
Emcure Pharmaceuticals IPO (Emcure Pharma IPO) Registrar
• Registrar: Link Intime India Private Ltd
• Phone: +91-22-4918 6270
• Email: emcure.ipo@linkintime.co.in
• Website: Link Intime
Emcure Pharmaceuticals IPO (Emcure Pharma IPO) Allotment Status
Check Emcure Pharmaceuticals IPO allotment status on the Link Intime website. Click Here
Emcure Pharmaceuticals IPO Lead Managers
• Kotak Mahindra Capital Company Limited
• Axis Capital Limited
• J.P. Morgan India Private Limited
• Jefferies India Private Limited
Company Address
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune – 411 057
Phone: +91 20 3507 0033
Email: investors@emcure.co.in
Website: Emcure Pharmaceuticals
Emcure Pharmaceuticals IPO (Emcure Pharma IPO) FAQs
1. What are the IPO dates for Emcure Pharmaceuticals?
The Emcure Pharmaceuticals IPO opens on July 3, 2024, and closes on July 5, 2024.
2. When will the share allotment be finalized?
The share allotment for the Emcure Pharmaceuticals IPO will be finalized on July 8, 2024.
3. When is the listing date for Emcure Pharmaceuticals?
Emcure Pharmaceuticals is expected to be listed on the stock exchange on July 10, 2024.
4. How much is Emcure Pharmaceuticals planning to raise through the IPO?
Emcure Pharmaceuticals aims to raise approximately ₹1952.03 crores through the IPO, which includes a fresh issue of ₹800 crores and an offer for sale of up to 11,428,839 equity shares.
5. What is the price of each equity share?
Each equity share is priced at ₹5.
6. What are the quota allocations for the IPO?
The retail investor quota is 35%, Qualified Institutional Buyers (QIB) quota is 50%, and the High Net-worth Individuals (HNI) quota is 15%.
7. What does Emcure Pharmaceuticals do?
Emcure Pharmaceuticals is an Indian pharmaceutical company involved in developing, manufacturing, and globally marketing a wide range of pharmaceutical products across major therapeutic areas.
8. What is unique about Emcure Pharmaceuticals’ product portfolio?
Emcure Pharmaceuticals has a differentiated product portfolio that includes orals, injectables, and biotherapeutics, which has enabled them to penetrate over 70 countries and maintain a strong presence in India, Europe, and Canada.
9. How is Emcure Pharmaceuticals ranked in the Indian pharmaceutical market?
In the MAT Financial Year 2024, Emcure Pharmaceuticals was the 13th largest pharmaceutical company in India by Domestic Sales, the 4th largest by market share in their Covered Markets, and the leading company in gynecology and HIV antivirals in India (Source: CRISIL Report).
10. What are the key therapeutic areas for Emcure Pharmaceuticals?
Emcure Pharmaceuticals has established a significant presence in gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related, and oncology/anti-neoplastics therapeutic areas.
11. How does Emcure Pharmaceuticals generate its revenue?
Sales of iron, chiral, biotherapeutics, injectables, and photochemistry products contributed to 52.97% of their revenue from sales in India for the Financial Year 2024. Chronic therapeutic areas contributed to ₹25,460.48 million or 46.22% of their total Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
12. Who leads Emcure Pharmaceuticals?
Emcure Pharmaceuticals is led by experienced promoters in the pharmaceutical industry and is supported by a strong professional management team.
